SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Establishing a reasonable price for an orphan drug
13 references·1 citing·51 second hop
Establishing a reasonable price for an orphan drug (2020)Establishing a reasonable price for an or…Comparing access to orphan medicinal products in Europe (2019)Comparing access to orphan me…Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016 (2018)Estimated Costs of Pivotal Tr…Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Innovation in the pharmaceuti…Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)Methods for the estimation of…Clinical development success rates for investigational drugs (2014)Clinical development success …Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context (2013)Value‐Based Differential Pric…A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines (2013)A Pilot Study of Multicriteri…What Is Wrong with Orphan Drug Policies? (2012)What Is Wrong with Orphan Dru…SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN (2012)SOCIETAL VIEWS ON NICE, CANCE…Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67 (2010)Societal views on orphan drug…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How to improve R&D productivi…Assessing the economic challenges posed by orphan drugs (2007)Assessing the economic challe…Orphan drugs and the NHS: should we value rarity? (2005)Orphan drugs and the NHS: sho…Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Potential approaches for the …The PHQ-9 (2001)Methods for the Economic Evaluation of Health Care Programmes (2005)A Brief Measure for Assessing Generalized Anxiety Disorder (2006)Cost–effectiveness thresholds: pros and cons (2016)The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought (2016)Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)Parallel imports, demand dispersion, and international price discrimination (1994)Economic foundations of cost-effectiveness analysis (1997)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness (2015)Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use (2016)Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis (2017)Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients (2001)QALY maximisation and people's preferences: a methodological review of the literature (2004)Response Rates and Nonresponse Errors in Surveys (2012)Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries (2014)Attributes and weights in health care priority setting: A systematic review of what counts and to what extent (2015)Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature (2017)The price of innovation: new estimates of drug development costs (2003)Can the pharmaceutical industry reduce attrition rates? (2004)Changing R&D models in research-based pharmaceutical companies (2016)A Comprehensive Map of FDA-Approved Pharmaceutical Products (2018)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)QALYfying the value of life. (1987)Explaining the Identifiable Victim Effect (1997)A rational framework for decision making by the National Institute For Clinical Excellence (NICE) (2002)Public healthcare resource allocation and the Rule of Rescue (2008)Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework (2017)Severity of illness and priority setting in healthcare: A review of the literature (2009)Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force (2011)Multiple Criteria Decision Analysis for Health Technology Assessment (2012)Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework (2014)Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment (2016)Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL) (2017)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)National Institute for Clinical Excellence and its value judgments (2004)Pricing and reimbursement of orphan drugs: the need for more transparency (2011)Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? (2012)Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries (2015)A Proof for the Queuing Formula: L = λ W (1961)The Goal: A Process of Ongoing Improvement (1984)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Cost-Effectiveness in Health and Medicine (1996)Essential medicines for universal health coverage (2016)The High Cost of Prescription Drugs in the United States (2016)Key cost drivers of pharmaceutical clinical trials in the United States (2016)Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017)Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies (2019)Generating comparative evidence on new drugs and devices after approval (2020)Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study (2020)
this work references cited by second hop

References

  • 2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,562 cited
  • 2016Innovation in the pharmaceutical industry: New estimates of R&D costs3,352 cited
  • 2014Clinical development success rates for investigational drugs2,531 cited
  • 2015Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold857 cited
  • 2018Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016356 cited
  • 2007Assessing the economic challenges posed by orphan drugs279 cited
  • 2005Orphan drugs and the NHS: should we value rarity?229 cited
  • 2012SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN208 cited
  • 2013Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context142 cited
  • 2013A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines111 cited
  • 2012What Is Wrong with Orphan Drug Policies?110 cited
  • 2010Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67103 cited
  • 2019Comparing access to orphan medicinal products in Europe88 cited

Cited by

  • 2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

75 cited